Now Enrolling:  LEGION-100 Phase 2 Trial for Metastatic Castration-Resistant Prostate Cancer.  Find A Location Near You ›

Synchronizing an
Attack on Cancer

Syncromune is developing a novel platform cancer immunotherapy that is delivered directly into a target tumor, designed to synchronize the immune system to recognize and destroy cancer throughout the body.

The Science

Learn more about the work our team is doing to unleash the immense therapeutic possibilities of SYNC-T in situ combination immunotherapy platform

Science

Clinical Trials

View information about our LEGION-100 trial that is evaluating the investigational SYNC-T Therapy SV-102 in metastatic castration-resistant prostate cancer

Trials

News

Syncromune®, Inc. Presents Innovative SYNC-T Combination Immunotherapy Approach at Major European Interventional Oncology Conference

Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer

Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting

Newsroom

Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.

Clinical Trials

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308

info@syncromune.com